Summary

Rare Disease Clinical Trials Market: Global Industry Analysis 2018-2022 and Opportunity Assessment 2023-2033

A recent market study published by FMI on Rare Disease Clinical Trials offers a global industry analysis for 2018-2022 and opportunity assessment for 2023-2033. The study offers a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historical and current growth parameters, the growth prospects of the market are obtained with maximum precision.

Market Segmentation

By Therapeutic Area:

• Oncology
• Cardiovascular Disorders
• Neurological Disorders
• Infectious Disease
• Genetic Disorders
• Autoimmune And Inflammation
• Hematologic Disorders
• Musculoskeletal Disorders
• Others

By Phase:

• Phase I
• Phase II
• Phase III
• Phase IV

By Sponsor:

• Pharmaceutical & Biopharmaceutical Companies
• Non-profit Organizations
• Others

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• MEA

Report Chapters

Executive Summary

The executive summary of the Rare Disease Clinical Trials Market includes the global market outlook, demand side trends, supply side trends and also include FMI analysis and recommendations of Vehicle Radar Test System.

Chapter 01 - Market Overview

Readers can find the detailed segmentation and definition of the Rare Disease Clinical Trials Market in this chapter, which will help to understand basic information about Vehicle Radar Test System. This section also highlights the market scope, taxonomy and limitations which help the reader understand the market coverage of Rare Disease Clinical Trials Market report.

Chapter 02 - Market Background

This chapter includes detailed analysis of the By Therapeutic Area processing methods overview, consumer buying patterns & tendencies and policy developments and regulatory scenario. It also includes in depth analysis of macro-economic factors and covers topics like global GDP growth outlook, global industry value added, personal consumption, expenditures, modern trade penetration and consumer price indices. The chapter also covers forecast factors - relevance & impact, value chain analysis and market dynamics (drivers, restraints and opportunities) to better understand the market.

Chapter 03 - Global Rare Disease Clinical Trials Market Demand Analysis 2018-2022 and Forecast, 2023-2033

The chapter include historical market value (US$ 11,455.0 million) analysis (2018-2022) and current and future market value (US$ 12,566.14 million) and volume (9.7%) projections (2023-2033). The projections are based on the Y-O-Y growth trend analysis and absolute $ opportunity analysis country of operation.

Chapter 04 - Global Rare Disease Clinical Trials Market - Pricing Analysis

Based on By Therapeutic Area, the pricing analysis chapter include Regional pricing analysis (USD/MT), global average pricing analysis benchmark, and key factors impacting the pricing.

Chapter 05 - Global Rare Disease Clinical Trials Market Analysis 2018-2022 and Forecast 2023-2033, By Therapeutic Area

Based on By Therapeutic Area, Rare Disease Clinical Trials Market is segmented into Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Disease, Genetic Disorders, Autoimmune And Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Others. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Therapeutic Area.

Chapter 06 - Global Rare Disease Clinical Trials Market Analysis 2018-2022 and Forecast 2023-2033, By Phase

Based on By Phase, Rare Disease Clinical Trials Market is segmented into Phase I, Phase II, Phase III, Phase IV. This section also offers market attractiveness analysis based on By Phase. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Phase.

Chapter 07 - Global Rare Disease Clinical Trials Market Analysis 2018-2022 and Forecast 2023-2033, By Sponsor

Based on By Sponsor, Rare Disease Clinical Trials Market is segmented into Pharmaceutical & Biopharmaceutical Companies, Non-profit Organizations, Others. This section also offers market attractiveness analysis based on By Sponsor. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Sponsor.

Chapter 08 - Rare Disease Clinical Trials Market Analysis 2018-2022 and Forecast 2023-2033, By Region

Based on By Region, Rare Disease Clinical Trials Market is segmented into North America, Latin America, Europe, East Asia, South Asia, Oceania and MEA. This section also offers market attractiveness analysis based on By Region. Readers can also find value forecast and Y-o-Y growth comparison for all above mentioned By Region.

Chapter 09 - North America Rare Disease Clinical Trials Market Analysis 2018-2022 and Forecast 2023-2033

This chapter includes a detailed analysis of the growth of the Vehicle Radar Test System in the North American region, along with a country-wise assessment that includes the US and Canada. Readers can also find regional trends, regulations, and market growth based on different segment and countries in the North America region.

Chapter 10 - Latin America Rare Disease Clinical Trials Market Analysis 2018-2022 and Forecast 2023-2033

This chapter includes a detailed analysis of the growth of Vehicle Radar Test System in the Latin America region, along with a country-wise assessment that includes the Brazil, Mexico, Chile, Argentina, Peru and Rest of Latin America. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Rare Disease Clinical Trials Market in the Latin America region.

Chapter 11 - Europe Rare Disease Clinical Trials Market Analysis 2018-2022 and Forecast 2023-2033

This chapter includes a detailed analysis of the growth of Vehicle Radar Test System in the European region, along with a country-wise assessment that includes the Germany, Italy, France, U.K., Spain, Russia, Nordic, Benelux and Rest of Europe. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Rare Disease Clinical Trials Market in the regional market.

Chapter 12 - East Asia Rare Disease Clinical Trials Market Analysis 2018-2022 and Forecast 2023-2033

This chapter includes a detailed analysis of the growth of Vehicle Radar Test System in the East Asia region, along with a country-wise assessment that includes the China, Japan, and South Korea. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Rare Disease Clinical Trials Market in the regional market.

Chapter 13 - South Asia Rare Disease Clinical Trials Market Analysis 2018-2022 and Forecast 2023-2033

This chapter includes a detailed analysis of the growth of Vehicle Radar Test System in the South Asia region, along with a country-wise assessment that includes the India, Indonesia, Malaysia, Thailand, and Rest of South Asia. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Rare Disease Clinical Trials Market in the regional market.

Chapter 14 - Middle East and Africa Rare Disease Clinical Trials Market Analysis 2018-2022 and Forecast 2023-2033

This chapter includes a detailed analysis of the growth of Vehicle Radar Test System in the MEA region, along with a country-wise assessment that includes the GCC Countries, South Africa, North Africa, Turkey and Rest of MEA. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Rare Disease Clinical Trials Market in the regional market.

Chapter 15 - Key Countries Rare Disease Clinical Trials Market Analysis 2018-2022 and Forecast 2023-2033

This chapter offers insights into how the Rare Disease Clinical Trials Market is expected to grow in major countries globally.

Chapter 16 - Market Structure Analysis- Global Assessment

This chapter includes company dashboard, industry structure analysis by tier of companies, 2022E, company share analysis of top players, 2022E, and competition benchmarking- matrix.

Chapter 17 - Competition Deep Dive (Tentative List)

This chapter includes company overview, By Therapeutic Area portfolio of companies, profitability by market segments, sales footprint, SWOT analysis and strategy overview of the companies being studied in the report. Some of the market players featured in the report are Takeda Pharmaceutical Company, F. Hoffmann-La Roche Ltd., Pfizer, Inc., AstraZeneca, Novartis AG, LabCorp, IQVIA, Inc., Charles River Laboratories, Icon PLC, Parexel International Corporation.

Chapter 18 - Assumptions and Acronyms

This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the Vehicle Radar Test System report.

Chapter 19 - Research Methodology

This chapter helps readers understand the research methodology followed to obtain various conclusions, as well as important qualitative and quantitative information, on Rare Disease Clinical Trials Market.

ページTOPに戻る

Table of Contents

1. Executive Summary | Rare Disease Clinical Trials Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapeutic Area

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Therapeutic Area, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapeutic Area, 2023 to 2033

        5.3.1. Oncology

        5.3.2. Cardiovascular Disorders

        5.3.3. Neurological Disorders

        5.3.4. Infectious Disease

        5.3.5. Genetic Disorders

        5.3.6. Autoimmune And Inflammation

        5.3.7. Hematologic Disorders

        5.3.8. Musculoskeletal Disorders

        5.3.9. Others

    5.4. Y-o-Y Growth Trend Analysis By Therapeutic Area, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Therapeutic Area, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Phase

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Phase, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Phase, 2023 to 2033

        6.3.1. Phase I

        6.3.2. Phase II

        6.3.3. Phase III

        6.3.4. Phase IV

    6.4. Y-o-Y Growth Trend Analysis By Phase, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Phase, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Sponsor

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Sponsor, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Sponsor, 2023 to 2033

        7.3.1. Pharmaceutical & Biopharmaceutical Companies

        7.3.2. Non-profit Organizations

    7.4. Y-o-Y Growth Trend Analysis By Sponsor, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Sponsor, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. South Asia

        8.3.5. East Asia

        8.3.6. Oceania

        8.3.7. MEA

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Therapeutic Area

        9.2.3. By Phase

        9.2.4. By Sponsor

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Therapeutic Area

        9.3.3. By Phase

        9.3.4. By Sponsor

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Therapeutic Area

        10.2.3. By Phase

        10.2.4. By Sponsor

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Therapeutic Area

        10.3.3. By Phase

        10.3.4. By Sponsor

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United kingdom

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Therapeutic Area

        11.2.3. By Phase

        11.2.4. By Sponsor

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Therapeutic Area

        11.3.3. By Phase

        11.3.4. By Sponsor

    11.4. Key Takeaways

12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Malaysia

            12.2.1.3. Singapore

            12.2.1.4. Thailand

            12.2.1.5. Rest of South Asia

        12.2.2. By Therapeutic Area

        12.2.3. By Phase

        12.2.4. By Sponsor

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Therapeutic Area

        12.3.3. By Phase

        12.3.4. By Sponsor

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Therapeutic Area

        13.2.3. By Phase

        13.2.4. By Sponsor

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Therapeutic Area

        13.3.3. By Phase

        13.3.4. By Sponsor

    13.4. Key Takeaways

14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. Australia

            14.2.1.2. New Zealand

        14.2.2. By Therapeutic Area

        14.2.3. By Phase

        14.2.4. By Sponsor

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Therapeutic Area

        14.3.3. By Phase

        14.3.4. By Sponsor

    14.4. Key Takeaways

15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Therapeutic Area

        15.2.3. By Phase

        15.2.4. By Sponsor

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Therapeutic Area

        15.3.3. By Phase

        15.3.4. By Sponsor

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Therapeutic Area

            16.1.2.2. By Phase

            16.1.2.3. By Sponsor

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Therapeutic Area

            16.2.2.2. By Phase

            16.2.2.3. By Sponsor

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Therapeutic Area

            16.3.2.2. By Phase

            16.3.2.3. By Sponsor

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Therapeutic Area

            16.4.2.2. By Phase

            16.4.2.3. By Sponsor

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Therapeutic Area

            16.5.2.2. By Phase

            16.5.2.3. By Sponsor

    16.6. United kingdom

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Therapeutic Area

            16.6.2.2. By Phase

            16.6.2.3. By Sponsor

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Therapeutic Area

            16.7.2.2. By Phase

            16.7.2.3. By Sponsor

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Therapeutic Area

            16.8.2.2. By Phase

            16.8.2.3. By Sponsor

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Therapeutic Area

            16.9.2.2. By Phase

            16.9.2.3. By Sponsor

    16.10. India

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Therapeutic Area

            16.10.2.2. By Phase

            16.10.2.3. By Sponsor

    16.11. Malaysia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Therapeutic Area

            16.11.2.2. By Phase

            16.11.2.3. By Sponsor

    16.12. Singapore

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Therapeutic Area

            16.12.2.2. By Phase

            16.12.2.3. By Sponsor

    16.13. Thailand

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Therapeutic Area

            16.13.2.2. By Phase

            16.13.2.3. By Sponsor

    16.14. China

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Therapeutic Area

            16.14.2.2. By Phase

            16.14.2.3. By Sponsor

    16.15. Japan

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Therapeutic Area

            16.15.2.2. By Phase

            16.15.2.3. By Sponsor

    16.16. South Korea

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Therapeutic Area

            16.16.2.2. By Phase

            16.16.2.3. By Sponsor

    16.17. Australia

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Therapeutic Area

            16.17.2.2. By Phase

            16.17.2.3. By Sponsor

    16.18. New Zealand

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Therapeutic Area

            16.18.2.2. By Phase

            16.18.2.3. By Sponsor

    16.19. GCC Countries

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Therapeutic Area

            16.19.2.2. By Phase

            16.19.2.3. By Sponsor

    16.20. South Africa

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Therapeutic Area

            16.20.2.2. By Phase

            16.20.2.3. By Sponsor

    16.21. Israel

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Therapeutic Area

            16.21.2.2. By Phase

            16.21.2.3. By Sponsor

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Therapeutic Area

        17.3.3. By Phase

        17.3.4. By Sponsor

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Takeda Pharmaceutical Company

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. F. Hoffmann-La Roche Ltd.

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Pfizer, Inc.

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. AstraZeneca

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Novartis AG

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. LabCorp

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. IQVIA

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Charles River Laboratories Inc.

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Icon PLC

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. Parexel International Corporation

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology